Trademark: 97148593
Word
GPCR NATIVE COMPLEX
Status
Dead
Status Code
602
Status Date
Wednesday, December 20, 2023
Serial Number
97148593
Mark Type
4000
Filing Date
Tuesday, November 30, 2021
Abandoned Date
Thursday, November 2, 2023

Trademark Owner History

Classifications
40 Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders
5 Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for use in medical research
1 Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific research use; chemical reagents for use in genetic research
44 Providing a website featuring information about the treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders
42 Bio-technology and scientific services, namely, research, and production and development services relating to bio-technology and science, namely, G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical research and development; Scientific and technological services, namely, biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research services, namely, treating therapeutic targets through chemical and biochemical preparations
G PROTEIN COUPLED RECEPTORS NATIVE COMPLEX

Trademark Events
Dec 21, 2023
Abandonment Notice E-Mailed - Failure To Respond
Dec 20, 2023
Abandonment Notice E-Mailed - Failure To Respond
Dec 20, 2023
Abandonment - Failure To Respond Or Late Response
Jul 20, 2023
Application Extension Granted/Receipt Provided
Jul 20, 2023
Application Extension To Response Period - Received
May 1, 2023
Notification Of Final Refusal Emailed
May 1, 2023
Final Refusal E-Mailed
May 1, 2023
Final Refusal Written
Mar 15, 2023
Teas/Email Correspondence Entered
Mar 13, 2023
Correspondence Received In Law Office
Mar 13, 2023
Teas Response To Office Action Received
Sep 13, 2022
Notification Of Non-Final Action E-Mailed
Sep 13, 2022
Non-Final Action E-Mailed
Sep 13, 2022
Non-Final Action Written
Sep 9, 2022
Assigned To Examiner
Dec 3, 2021
New Application Office Supplied Data Entered
Dec 3, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24